Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, ...
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects ...
The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback